New Delhi, February 23
Drug maker Lupin on Monday announced that it has received approval from the European Commission for its biosimilar Ranluspec, used in the treatment of several serious eye conditions.
The approval follows a recent positive opinion from the Committee for Medicinal Products for Human Use, clearing the way for commercialization across the European Union.
Ranluspec Approved for Multiple Retinal Conditions
Ranluspec is a biosimilar version of ranibizumab and is indicated for the treatment of:- Neovascular or wet age-related macular degeneration
- Macular edema following retinal vein occlusion
- Diabetic macular edema
- Proliferative diabetic retinopathy
- Choroidal neovascularization
Commercialization Strategy Across the European Union
Lupin’s biosimilar ranibizumab will be commercialized by Sandoz across the European Union, excluding Germany.In France, the product will be marketed by two companies, Sandoz and Biogaran.
Commenting on the development, Lupin President EMEA and Emerging Markets Thierry Volle said the approval underscores the company’s scientific capabilities and manufacturing excellence.
Lupin Shares Close Higher
Following the announcement, Lupin shares ended 1.14 per cent higher at Rs 2,245.10 apiece on the BSE on Monday.The European Commission approval marks a significant regulatory milestone for Lupin as it advances its biosimilars footprint in key international markets.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Last edited by a moderator: